NewBioRx provides Certificates of Analysis for research compounds to document analytical verification and batch characteristics
The takeaway from that table is the whole point of an honest comparison: the two rows with real strength each describe only one drug, the direct cagrilintide-vs-retatrutide row is empty, and the only cross-drug row is explicitly weak
What smart employers are doing now Pair the prescriptions with proven behavioral + nutrition coaching Track outcomes, not claims Fund prevention at the same level as treatment Treat metabolic health as a strategic asset, not a perk If you were redesigning benefits today would you start with drugs, or with human-centered health foundations
1 Among those who have been diagnosed with overweight or obesity by a healthcare provider, this figure increases to 22%
10,33 With regard to the secondary outcome of HF hospitalisation, the results were neutral, with LEADER showing a non-significant relative risk reduction (RRR) of 13% with liraglutide compared with placebo and SUSTAIN-6 showing no significant difference between the semaglutide and placebo treatment groups
1 Morgan Stanley, Could Obesity Drugs Take a Bite Out of the Food Industry, 2023 2 Morgan Stanley, 2023 3 The Food Institute, 2024 4 Nestle, First-to-market Vital Pursuit Hits Shelves Nationwide, 2024 5 Grocery Dive, How GLP-1s Could Reshape the Grocery Store, 2025 6 MediaRadar, Weight Loss, Diabetes Drug Ad Spending Tops $1B, 2024 7 McKinsey, What are GLP-1 Medications?, 2025 8 JP Morgan Research, The Increase in Appetite for Obesity Drugs, 2023 9 Cornell University, The No-Hunger Games: How GLP-1 Medication Adoption is Changing Consumer Food Demand, 2024
